RECOVERY trial: In hospitalized COVID-19 patients with hypoxia and systemic inflammation (C-reactive protein ≥75 mg/L), tocilizumab improved survival and other clinical outcomes
3 May, 2021 | 05:47h | UTCInvited commentary: Tocilizumab in COVID-19: some clarity amid controversy – The Lancet